Gerd Auffarth Net Worth

Gerd Auffarth biography

Dr. Gerd Auffarth serves as Director of the Company. Dr. Auffarth is an internationally recognized ophthalmologist in the area of research and development as well as clinical care for patients. He currently serves as the Medical Director of Heidelberg University Eye Clinic. Prior to his appointment as Medical Director in 2011, he worked as a senior physician at the University Eye Clinic. He currently serves as the Director of the International Vision Correction Research Center (IVCRC) and the David J. Apple Laboratory for Ocular Pathology, which he has established in the University Eye Clinic and which are recognized worldwide in the field of implant and biomaterial research. He is a board member of the German (General Secretary) and the European Society for Cataract and Refractive Surgery and is considered one of the most experienced surgeons in cataract and corneal surgery. As a co-founder of the Lions cornea bank in Heidelberg at the Heidelberg University Eye Clinic, Prof. Dr. Auffarth continued to advance transplant surgery (the human cornea) and innovative research areas at the Heidelberg site. In 2004 he was appointed Vice Chairman and Deputy Director of the Heidelberg Department of Ophthalmology; he was awarded Extraordinary Professorship in the Medical Faculty of the University of Heidelberg in May 2005.

What's Gerd Auffarth's mailing address?

Gerd's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830.

Insiders trading at Outlook Therapeutics Inc

Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv..., and Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.

What does Outlook Therapeutics Inc do?

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t

Outlook Therapeutics Inc executives and stock owners

Outlook Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lawrence Kenyon,
  President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
• Lawrence A. Kenyon CPA,
  Exec. VP, CFO, Treasurer, Company Sec. & Director
• C. Russell Trenary III,
  Pres, CEO & Director
• Randy Thurman,
  Executive Chairman of the Board
• Terry Dagnon,
  Chief Operations Officer
• Jeffrey Evanson,
  Chief Commercial Officer
• Ralph H. Thurman,
  Independent Exec. Chairman
• Jeremy Feffer,
  IR Contact Officer
• Faisal Sukhtian,
  Independent Director
• Kurt Hilzinger,
  Independent Director
• Yezan Haddadin,
  Independent Director
• Andong Huang,
  Director
• Julian Gangolli,
  Director
• Gerd Auffarth,
  Director
• Jeff Evanson,
  Chief Commercial Officer
• Terry Dagnon,
  Chief Operating Officer
• Alicia Tozier,
  Sr. VP, Marketing & Market Access
• Joel Prieve,
  Sr. VP of Commercial Operations
• Elizabeth A. Yamashita,
  Advisor
• Dr. Balu N. Balasubramanian,
  Advisor
• Rick Gregory,
  Director of Marketing & Communications
• C Russell Iii Trenary,
  CEO AND PRESIDENT
• Pte Ltd.Pillai Arun Kumar S...,
  
• Ghiath M.Gms Ventures & Inv...,
  
• Joe Thomas,
  Director
• Pte Ltd. Bio Lexis,
  10% owner
• Faisal Ghiath Gms Ventures ...,
  
• Arun Kumar Pillai,
  Director
• Ventures Llc Syntone,
  
• Julia A Haller,